Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5-year outcome

Francesca Palandri, Ilaria Iacobucci, Fausto Castagnetti, Nicoletta Testoni, Angela Poerio, Marilina Amabile, Massimo Breccia, Tamara Intermesoli, Francesco Iuliano, Giovanna Rege-Cambrin, Mario Tiribelli, Maurizio Miglino, Fabrizio Pane, Giuseppe Saglio, Giovanni Martinelli, Gianantonio Rosti, Michele Baccarani

Research output: Contribution to journalArticlepeer-review

Abstract

In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-α in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13%) had discontinued pegylated interferon-α. The complete cytogenetic response rate at five years was 87%, and 94% of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response. These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-a remains uncertain, due to low patient compliance.

Original languageEnglish
Pages (from-to)770-774
Number of pages5
JournalHaematologica
Volume93
Issue number5
DOIs
Publication statusPublished - May 2008

Keywords

  • Chronic myeloid leukemia
  • Imatinib
  • Interferon-alpha
  • Long-term results

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5-year outcome'. Together they form a unique fingerprint.

Cite this